BioToxTech Co

BioToxTech Co ROCE

The Return on Capital Employed (ROCE) of BioToxTech Co (086040.KQ) as of Nov 18, 2026 is -15.06 %. In the previous year, Return on Capital Employed (ROCE) was -13.63 % — a change of 10.49% (lower).

ROCE

-15.06 %

YoY

10.49%

Last updated:

In 2025, BioToxTech Co's return on capital employed (ROCE) was -15.06 %, a 10.49% increase from the -13.63 % ROCE in the previous year.

The BioToxTech Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
0.23 KRW
Jan 1, 2019
-4.34 KRW
Jan 1, 2020
1.60 KRW
Jan 1, 2021
10.10 KRW
Jan 1, 2022
2.21 KRW
Jan 1, 2023
-17.05 KRW
Jan 1, 2024
-13.63 KRW
Jan 1, 2025
-15.06 KRW
The BioToxTech Co ROCE history
YEARROCEYoY
-15.06 %+10.49%
-13.63 %-20.05%
-17.05 %-870.20%
2.21 %-78.09%
10.10 %+530.27%
1.60 %-136.94%
-4.34 %-2,020.92%
0.23 %-97.25%
8.22 %-0.51%
8.26 %-145.36%
-18.21 %+4.57%
-17.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling BioToxTech Co's Return on Capital Employed (ROCE)

BioToxTech Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing BioToxTech Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

BioToxTech Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in BioToxTech Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about BioToxTech Co stock

Return on Capital Employed (ROCE) of BioToxTech Co is -15.06 % in 2025.

Return on Capital Employed (ROCE) of BioToxTech Co changed from -13.63 % to -15.06 %, representing a 10.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioToxTech Co

All Key Metrics — BioToxTech Co